Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia – Drugs In Development, 2022, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 7, 6 and 13 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Neutropenia – Overview
Neutropenia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neutropenia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neutropenia – Companies Involved in Therapeutics Development
Akthelia Pharmaceuticals Ltd
Aprilbio Co Ltd
BeyondSpring Inc
Biocon Ltd
Biocure Technology Inc
Biosidus SA
Biosimilar Solutions LLC
Cellerant Therapeutics Inc
CPL Biologicals Pvt Ltd
CSPC Pharmaceutical Group Ltd
Dr. Reddy's Laboratories Ltd
EmendoBio Inc
Genova Biotech Company Ltd
Ilkogen Ilac San Ve Tic AS
InflaRx NV
Lupin Ltd
Merck & Co Inc
Mycenax Biotech Inc
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Qilu Pharmaceutical Co Ltd
Seres Therapeutics Inc
Shenzhen Xinpeng Bio-technology Co Ltd
Siam Bioscience Co Ltd
Statera Biopharma Inc
Tanvex BioPharma Inc
Toko Pharmaceutical Industries Co Ltd
USV Pvt Ltd
X4 Pharmaceuticals Inc
Neutropenia – Drug Profiles
(ceftolozane sulfate + tazobactam sodium) – Drug Profile
AKT-011 – Drug Profile
amphotericin B – Drug Profile
CBLB-612 – Drug Profile
EMD-101 – Drug Profile
entolimod – Drug Profile
filgrastim – Drug Profile
filgrastim biosimilar – Drug Profile
GXG-3 – Drug Profile
human granulocyte colony-stimulating factor biobetter – Drug Profile
INF-904 – Drug Profile
mavorixafor – Drug Profile
Nova-GM-CSF – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim – Drug Profile
pegfilgrastim biosimilar – Drug Profile
plinabulin – Drug Profile
posaconazole – Drug Profile
Recombinant Protein to Agonize GCSFR for Neutropenia – Drug Profile
romyelocel-L – Drug Profile
SER-155 – Drug Profile
ST-7 – Drug Profile
tamibarotene – Drug Profile
Neutropenia – Dormant Projects
Neutropenia – Discontinued Products
Neutropenia – Product Development Milestones
Featured News & Press Releases
Mar 29, 2022: EMA recommends granting a marketing authorisation for stimufend
Dec 08, 2021: Emendo Biotherapeutics to present new data at 63rd ASH Annual Meeting & Exhibition
Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor
Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results
Oct 12, 2020: BeyondSpring forms partnership advisory committee comprised of industry veterans
Sep 29, 2020: JAMA Oncology highlights plinabulin's efficacy in preventing chemotherapy-induced neutropenia as a monotherapy
May 27, 2020: FDA accepts for review Fresenius Kabi’s first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim
May 22, 2020: Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA
Apr 28, 2020: Mylan and Biocon launch Fulphila, Biosimilar Pegfilgrastim, in Canada
Apr 14, 2020: Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia
Nov 05, 2019: X4 Pharmaceuticals initiates phase 1b clinical trial of Mavorixafor for the treatment of severe Congenital Neutropenia
Sep 23, 2019: BeyondSpring’s Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention
Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia
May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019
May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Neutropenia, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Products under Development by Companies, 2022 (Contd..1)
Table 5: Number of Products by Stage and Target, 2022
Table 6: Number of Products by Stage and Mechanism of Action, 2022
Table 7: Number of Products by Stage and Route of Administration, 2022
Table 8: Number of Products by Stage and Molecule Type, 2022
Table 9: Neutropenia – Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Table 10: Neutropenia – Pipeline by Aprilbio Co Ltd, 2022
Table 11: Neutropenia – Pipeline by BeyondSpring Inc, 2022
Table 12: Neutropenia – Pipeline by Biocon Ltd, 2022
Table 13: Neutropenia – Pipeline by Biocure Technology Inc, 2022
Table 14: Neutropenia – Pipeline by Biosidus SA, 2022
Table 15: Neutropenia – Pipeline by Biosimilar Solutions LLC, 2022
Table 16: Neutropenia – Pipeline by Cellerant Therapeutics Inc, 2022
Table 17: Neutropenia – Pipeline by CPL Biologicals Pvt Ltd, 2022
Table 18: Neutropenia – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Table 19: Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, 2022
Table 20: Neutropenia – Pipeline by EmendoBio Inc, 2022
Table 21: Neutropenia – Pipeline by Genova Biotech Company Ltd, 2022
Table 22: Neutropenia – Pipeline by Ilkogen Ilac San Ve Tic AS, 2022
Table 23: Neutropenia – Pipeline by InflaRx NV, 2022
Table 24: Neutropenia – Pipeline by Lupin Ltd, 2022
Table 25: Neutropenia – Pipeline by Merck & Co Inc, 2022
Table 26: Neutropenia – Pipeline by Mycenax Biotech Inc, 2022
Table 27: Neutropenia – Pipeline by Phoenicia Biosciences Inc, 2022
Table 28: Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, 2022
Table 29: Neutropenia – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Table 30: Neutropenia – Pipeline by Seres Therapeutics Inc, 2022
Table 31: Neutropenia – Pipeline by Shenzhen Xinpeng Bio-technology Co Ltd, 2022
Table 32: Neutropenia – Pipeline by Siam Bioscience Co Ltd, 2022
Table 33: Neutropenia – Pipeline by Statera Biopharma Inc, 2022
Table 34: Neutropenia – Pipeline by Tanvex BioPharma Inc, 2022
Table 35: Neutropenia – Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022
Table 36: Neutropenia – Pipeline by USV Pvt Ltd, 2022
Table 37: Neutropenia – Pipeline by X4 Pharmaceuticals Inc, 2022
Table 38: Neutropenia – Dormant Projects, 2022
Table 39: Neutropenia – Dormant Projects, 2022 (Contd..1)
Table 40: Neutropenia – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Neutropenia, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings